Loading…
Based on limited metadata, CBD Gaze received an FDA Warning Letter on May 26, 2020, regarding compliance issues with a product categorized as "Other." Without access to the full letter text or a documented subject line, the specific nature of the violations cannot be determined from the available information. The issuing FDA office is also not specified in the metadata provided. To understand the regulatory concerns and required corrective actions, review of the complete Warning Letter would be necessary.